May 2 |
Blueprint Medicines Corp Reports Q1 2024 Earnings, Surpasses Revenue Estimates and Raises ...
|
May 2 |
Blueprint Medicines (BPMC) Reports Q1 Loss, Tops Revenue Estimates
|
May 2 |
Blueprint Medicines GAAP EPS of $1.40 beats by $3.05, revenue of $96.12M beats by $14.68M
|
May 2 |
Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
|
May 1 |
Blueprint Medicines Q1 2024 Earnings Preview
|
Apr 30 |
Will Apellis Pharmaceuticals, Inc. (APLS) Report Negative Earnings Next Week? What You Should Know
|
Apr 26 |
The Analyst Verdict: Blueprint Medicines In The Eyes Of 7 Experts
|
Apr 25 |
Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
|
Apr 18 |
Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024
|
Apr 11 |
Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics
|